BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update

BioHarvest posts modest revenue growth but losses widen as it pivots to manufacturing.

What the company is saying

BioHarvest Sciences Inc frames the quarter as a turning point, highlighting its first CDMO manufacturing agreement for a rare botanical fragrance and a $1.4M grant from the Israel Innovation Authority. The company emphasizes a strategic transition from technology validation to recurring manufacturing revenue, royalties, and sustainable profitability. It claims VINIA remains a stable, growing business with 95,000 active customers and points to a new pricing strategy as a margin driver. Revised guidance is presented as a sign of discipline, with tightened CDMO revenue expectations and a reduced EBITDA loss target. The announcement stresses the scale and value of the new fragrance agreement, the reallocation of capital to manufacturing, and a focus on margin over near-term revenue. The tone is confident and forward-looking, but most operational claims are framed as future outcomes rather than realised results.

What the data suggests

Q2 2026 revenue reached $8.8 million, a 3.8% year-over-year increase, indicating only modest top-line growth. Gross margins slipped slightly from 59% to 58%, while operating loss widened from $1.8 million to $2.5 million and adjusted EBITDA loss increased from $1.2 million to $1.6 million. Net loss improved marginally to $3.7 million from $4.1 million, and cash and equivalents surged to $16.25 million from $3.7 million a year earlier, largely due to external funding or grants. The VINIA D2C business grew revenue by just 2% year-over-year, and the first pricing change since 2021 was implemented, but its full-year guidance was cut from $38-$42 million to $33-$35 million, with EBITDA now expected to be a loss rather than a gain. The CDMO business’s revenue guidance was tightened to $4-$5 million, and full-year EBITDA loss guidance improved to $1.5m-$2.5 million, but these remain projections. Realised recurring manufacturing revenue or profitability from the new agreement is not yet evident in the numbers.

Analysis

The announcement is generally positive in tone, highlighting revenue growth, a new CDMO manufacturing agreement, and a government grant. However, the actual realised progress is modest: Q2 revenue grew only 3.8% year-over-year, gross margins were flat, and operating and EBITDA losses increased. The new manufacturing agreement is a milestone, but most of the anticipated benefits (recurring revenue, profitability, scale-up) are forward-looking and not yet realised. The company is redirecting capital into manufacturing capacity, but the financial impact of these investments is not immediate, and guidance revisions indicate ongoing losses. The narrative inflates the signal by emphasizing transition to profitability and recurring revenue, but the data shows continued losses and only incremental operational progress. The gap between narrative and evidence is moderate: while some milestones are real, the majority of claimed future benefits remain projections.

Risk flags

• ●Operational execution risk is high, as the company must deliver on a 20-ton production program for a rare fragrance ingredient over two years, a scale it has not previously achieved. Failure to meet production timelines or quality standards could jeopardize future CDMO revenue and reputation.
• ●Financial risk persists, with operating and EBITDA losses widening in Q2 2026 despite revenue growth. The company continues to burn cash, and while the cash position improved to $16.25 million, ongoing losses could erode this buffer if profitability is not reached soon.
• ●Disclosure risk is present, as the announcement lacks segment-specific revenue and profitability data for the new CDMO agreement, and most forward-looking claims about recurring revenue and margin expansion are not yet supported by realised results.
• ●Customer concentration risk exists in the CDMO business, as the new manufacturing agreement appears to be with a single fragrance customer. Reliance on one or a few customers for new revenue streams increases vulnerability to contract changes or cancellations.
• ●Guidance risk is notable, as both VINIA and consolidated EBITDA guidance were revised downward, reflecting lower expectations for near-term growth and profitability. If these revised targets are missed, investor confidence could deteriorate further.

Bottom line

BioHarvest’s Q2 update shows incremental revenue growth and a strengthened cash position, but losses are widening and the path to profitability remains unproven. The new CDMO manufacturing agreement is a milestone, but its financial impact is entirely forward-looking, with no realised recurring revenue or margin expansion yet visible. Revised guidance signals management discipline but also lower expectations for both the VINIA D2C and CDMO businesses in 2026. The company’s narrative is more optimistic than the underlying numbers, and most of the claimed transition to recurring revenue and profitability is still aspirational. Investors should focus on evidence of realised manufacturing revenue, margin improvement, and whether the company can deliver on its production commitments without further guidance downgrades. The most important takeaway is that BioHarvest remains in a capital-intensive, loss-making phase, and the credibility of its pivot to manufacturing will depend on execution and tangible financial results over the next 12–24 months.

Announcement summary

(NASDAQ: BHST) BioHarvest Sciences Inc announced results from the second quarter and six months of 2026, reporting $8.8 million in Q2 revenue, up 3.8% from Q2 2025. The company secured its first ever CDMO Manufacturing Agreement supporting a planned 20-ton commercial production program over two years for a rare botanical fragrance. Gross margins for the three months ended June 30, 2026 were 58% of revenue compared to 59% for the same period last year. Total operating loss for the three months ended June 30, 2026 was $2.5 million compared to $1.8 million for the same period last year. Net loss for the three months ended June 30, 2026 was $3.7 million compared to $4.1 million for the same period last year. BioHarvest was awarded a $1.4M Grant from the Israel Innovation Authority (IIA) in July to support predictive AI and manufacturing scale-up. The company revised full-year 2026 guidance, tightening the CDMO business expected revenue range to $4-$5 million and reducing expected full-year EBITDA loss to $1.5m - $2.5 million.

Disagree with this article?